

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property

Organization

International Bureau

(43) International Publication Date

01 August 2019 (01.08.2019)



(10) International Publication Number

WO 2019/147094 A1

(51) International Patent Classification:

A61K 9/28 (2006.01) A61K 9/50 (2006.01)  
A61K 9/20 (2006.01) A61K 31/4439 (2006.01)  
A61K 9/16 (2006.01) A61P 1/04 (2006.01)

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(21) International Application Number:

PCT/KR2019/001183

(22) International Filing Date:

28 January 2019 (28.01.2019)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

10-2018-0010987 29 January 2018 (29.01.2018) KR

(71) Applicant: **CHONG KUN DANG PHARMACEUTICAL CORP.** [KR/KR]; 8, Chungjeong-ro, Seodaemun-gu, Seoul 03742 (KR).

(72) Inventors: **CHOI, Jong Seo**; 315-20, Dongbaekjukjeon-daero, Giheung-gu, Yongin-si, Gyeonggi-do 16995 (KR). **KIM, Min Soo**; 315-20, Dongbaekjukjeon-daero, Giheung-gu, Yongin-si, Gyeonggi-do 16995 (KR). **PARK, Shin Jung**; 315-20, Dongbaekjukjeon-daero, Giheung-gu, Yongin-si, Gyeonggi-do 16995 (KR). **LIM, Jong Lae**; 315-20, Dongbaekjukjeon-daero, Giheung-gu, Yongin-si, Gyeonggi-do 16995 (KR).

(74) Agent: **CHOI, Eun Sun**; 5F, SungwonTower, 28, Yeongdong-daero 85-gil, Gangnam-gu, Seoul 06180 (KR).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: PHARMACEUTICAL FORMULATION COMPRISING ESOMEPRAZOLE AND SODIUM BICARBONATE

(57) Abstract: The present invention relates to a stable pharmaceutical formulation comprising omeprazole, its enantiomer, or its pharmaceutically acceptable salt, and sodium bicarbonate, and a method for preparing the same. Specifically, the present invention provides a stable formulation by preventing omeprazole, its enantiomer, or its pharmaceutically acceptable salt, from coming in direct contact with sodium bicarbonate, to reduce the production of impurities.



WO 2019/147094 A1

## Description

### Title of Invention: PHARMACEUTICAL FORMULATION COMPRISING ESOMEPRAZOLE AND SODIUM BI- CARBONATE

#### Technical Field

- [1] The present invention relates to a stable pharmaceutical formulation comprising omeprazole, its enantiomer, or its pharmaceutically acceptable salt, and sodium bicarbonate, and the method for preparing the same. Specifically, the present invention provides a stable formulation by preventing omeprazole, its enantiomer, or its pharmaceutically acceptable salt from coming in direct contact with sodium bicarbonate, to reduce the production of impurities.

#### Background Art

- [2] Omeprazole has a chemical name of 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl-1H-benzimidazol. Omeprazole exists in the two types of isomers: R-isomer and S-isomer. S-isomer is known for being remarkably excellent in terms of the treatment effect and side effects in comparison with R-isomer. S-isomer refers to (S)-5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl-1H-benzimidazol, which is commonly called esomeprazole.
- [3] Esomeprazole is a representative proton-pump inhibitor (PPI) which is used for the treatment of dyspepsia, peptic ulcer disease, gastroesophageal reflux disease, Zollinger-Ellison syndrome, and the like.
- [4] It is well known in the art that omeprazole, especially, esomeprazole, is prone to degradation or transformation in acidic and neutral media. More particularly, esomeprazole is known to have less than 10 minutes of a degradation half-life in an aqueous solution having 3 or lower of pH. As such, decomposition of esomeprazole is catalyzed by an acidic compound, and also affected by moisture, heat, organic solvents, and light.
- [5] Thus, there have been a lot of demands on a stable esomeprazole formulation. In order to solve the stability issue, Korean Patent No. 384960 discloses a method of preparing a pellet comprising a magnesium salt of esomeprazole, followed by enteric coating, adding excipients, and formulating as a tablet. The formulation as prepared based on the method described above is currently being marketed under the trade name of Nexium®.
- [6] However, an enteric-coated tablet such as Nexium® is not suitable for the treatment of diseases requiring immediate therapeutic effect after administration, such as gastric

acid-related diseases, because it was designed to be dissolved and absorbed in the intestine while not causing immediate absorption in the stomach.

[7] Korean Patent No. 1104349 discloses an enteric-coated tablet and capsule wherein the insufficiency of the stability and properties of omeprazole was improved by preparing a solid dispersion formulation with magnesium oxide and povidone.

[8] Korean Patent Publication No. 10-1996-0003605 discloses a method for preparing a solid dispersion formulation comprising omeprazole as an active ingredient wherein beta-cyclodextrin and sodium hydroxide are added as a stabilizing ingredient. However, the invention as described in the above undesirably uses sodium hydroxide which is harmful to human body. The process of preparing the solid dispersion comprises dissolving the active ingredient, omeprazole, in a solvent, wherein a special stabilizer such as sodium hydroxide is required to stabilize omeprazole.

[9] To solve these problems, Korean Patent No. 679767 discloses a method of using a buffering agent such as sodium bicarbonate for omeprazole.

[10] However, the use of a large amount of sodium bicarbonate has the disadvantage of reducing the efficacy of omeprazole and causing side effects. In particular, when sodium bicarbonate is administered in a large amount, the stomach may be swollen to further increase pain in a critical patient. The absorption of sodium bicarbonate may induce burping while the burping may cause gastric acid to move upward, whereby deteriorating gastroesophageal reflux disease. Further, patients with symptoms such as hypertension or heart failure should avoid the intake of sodium which may result in hypertensive symptoms. As such, it is not appropriate to administer a large amount of sodium bicarbonate to patients with these symptoms. In addition, the administration of a large amount of sodium bicarbonate to patients with various complications is at risk of causing metabolic alkalemia. Moreover, because buffering agents that alter pH of the stomach and urine may affect an absorption, distribution, and metabolic process of a drug, the use of a large amount of sodium bicarbonate with omeprazole requires more attention.

[11] Further, since the compatibility between omeprazole or its enantiomer, and sodium bicarbonate is not good, contacting each other may cause increased impurities.

## **Disclosure of Invention**

### **Technical Problem**

[12] The inventors have developed a formulation comprising sodium bicarbonate as an antacid that increases intragastric pH so as to stabilize omeprazole or its enantiomer which is unstable at a low pH. However, in order to solve the problem of the compatibility that may be caused by simultaneously comprising omeprazole or its enantiomer and sodium bicarbonate, we tried to apply different coating agents through

the experiments and research for a long period to confirm that polyvinyl alcohol is most appropriate, based on which the present invention was achieved.

- [13] It was also confirmed that polyvinyl alcohol not only prevents omeprazole or its enantiomer from coming in contact with sodium bicarbonate to improve stability of a formulation, but also is used for coating the outer part of a tablet to further enhance stability of a formulation. As such, a formulation having very improved stability has been developed.

### **Solution to Problem**

- [14] The present invention relates to a pharmaceutical formulation comprising omeprazole, its enantiomer, or its pharmaceutically acceptable salt, and sodium bicarbonate, and further comprising polyvinyl alcohol as a coating agent.
- [15] Omeprazole may be in any enantiomer type of S-isomer or R-isomer, preferably, S-isomer, i.e., esomeprazole.
- [16] The term "a pharmaceutically acceptable salt" as used herein may be, but is not limited to, a metal salt comprising sodium, potassium, calcium, magnesium, zinc, lithium, etc., or an ammonium salt. Among them, a magnesium salt is preferable.
- [17] Omeprazole, its enantiomer, or its pharmaceutically acceptable salt may be in a solvate comprising hydrates such as monohydrate, dihydrate, or trihydrate, and may be in an amorphous or crystal form.
- [18] Sodium bicarbonate may be used as an antacid to stabilize omeprazole or its enantiomer that is unstable at a low pH.
- [19] The coating agent according to the present invention separates and/or prevents omeprazole, its enantiomer, or its pharmaceutically acceptable salt from coming in direct contact with sodium bicarbonate, so that it plays a role in improving compatibility.
- [20] The present invention relates to a pharmaceutical formulation, characterized in comprising the first layer comprising omeprazole, its enantiomer, or its pharmaceutically acceptable salt; the second layer comprising polyvinyl alcohol as a coating agent; and the third layer comprising sodium bicarbonate as an antacid.
- [21] Further, the coating agent according to the present invention is used for coating the outer part of a formulation, so that it plays a role in improving stability.
- [22] Further, the present invention relates to a pharmaceutical formulation further comprising the fourth layer comprising polyvinyl alcohol as a coating agent.
- [23] The coating agent in the above second and fourth layers may be comprised in 0.1 to 7 parts by weight, preferably, 0.5 to 5 parts by weight based on 1 part by weight of omeprazole, its enantiomer, or its pharmaceutically acceptable salt.
- [24] A pharmaceutical formulation according to the present invention may be prepared

based the following steps:

- [25] first coating a core with a coating solution comprising omeprazole, its enantiomer, or its pharmaceutically acceptable salt to prepare a first coated material;
- [26] coating the first coated material with a second coating solution comprising polyvinyl alcohol to prepare a second coated material;
- [27] tableting the second coated material with sodium bicarbonate to prepare a core tablet; and
- [28] coating the core tablet with a third coating solution comprising polyvinyl alcohol.
- [29] More Specifically, the present invention relates to a pharmaceutical formulation comprising 20 mg or 40 mg of esomeprazole magnesium trihydrate based on the weight of esomeprazole, and 800 mg of sodium bicarbonate, which may be prepared based on the following steps:
- [30] first coating a core with a coating solution comprising esomeprazole magnesium trihydrate to prepare a first coated material;
- [31] coating the first coated material with a second coating solution comprising polyvinyl alcohol to prepare a second coated material;
- [32] tableting the second coated material with sodium bicarbonate to prepare a core tablet; and
- [33] coating the core tablet with a third coating solution comprising polyvinyl alcohol.

### **Advantageous Effects of Invention**

- [34] The present invention relates to a pharmaceutical formulation with improved stability, comprising omeprazole, its enantiomer, or its pharmaceutically acceptable salt, and sodium bicarbonate. In the pharmaceutical formulation according to the present invention, omeprazole is prevented from coming in contacting with sodium bicarbonate to improve compatibility, while a tableted tablet is coated to further improve stability.
- [35] The formulation according to the present invention is prepared in a monolayered tablet, which results in easy preparation and improved stability. Further, the formulation is immediately dissolved and absorbed in the stomach to have improved dissolution rate and bioavailability.

### **Mode for the Invention**

- [36] Hereinafter, the present invention will be more detailed through the following examples. However, the examples are merely provided for a better understanding of the present invention for the purpose of illustration, but are not to be construed as the limitation of the claimed scope.

[37]

[38] **[Example1]**

[39] Preparation of a tablet of esomeprazole comprising PVA (polyvinyl alcohol) as a coating agent

[40]

[41] A tablet of esomeprazole comprising PVA was prepared based on the method as follows.

[42]

[43] **1. First coating**

[44] Hydroxypropyl cellulose was added and dissolved in purified water, followed by adding arginine, simethicone, purified water, esomeprazole magnesium trihydrate (22.3 mg; 20.00 mg based on the weight of esomeprazole), magnesium oxide, and talc, and dispersing them, to prepare a coating solution. Sugar spheres were put into a fluidized bed granulation-coating machine, spraying the coating solution, to prepare a first coated material.

[45]

[46] **2. Second coating**

[47] Polyvinyl alcohol (7.4 mg; 0.7 wt% based on the total weight of the tablet), talc, titanium oxide, glycerol monocaprylocaprate, and sodium lauryl sulfate were added and dispersed in purified water to prepare a coating solution. The first coated materials from the first coating process were put into a fluidized bed granulation-coating machine, spraying the coating solution, to prepare a second coated material.

[48]

[49] **3. Blending and tableting**

[50] The second coated material, sodium bicarbonate (800 mg), copovidone, and crospovidone were put in a mixer to be blended, followed by adding sodium stearyl fumarate and lubricating to prepare granules. The prepared granules were tableted.

[51]

[52] **4. Third coating**

[53] Polyvinyl alcohol (15.5 mg; 1.5 wt% based on the total weight of the tablet), talc, titanium oxide, glycerol monocaprylocaprate, sodium lauryl sulfate, red iron oxide, black iron oxide, and yellow iron oxide were added in purified water to prepare a coating solution. The core tablets were put into a coating machine, spraying the coating solution, coating, and drying to obtain the final film coated tablet.

[54]

[55] **[Comparative Example 1]**

[56] Preparation of a tablet of esomeprazole comprising hydroxypropyl methylcellulose as a coating agent

[57] The tablet was prepared based on the following method, provided that hydroxypropyl methylcellulose was used as a coating agent for the second and third coating steps,

instead of polyvinyl alcohol used in Example 1.

[58]

[59] **1. First coating**

[60] Hydroxypropyl cellulose was added and dissolved in purified water, followed by adding simethicone, esomeprazole magnesium trihydrate, magnesium oxide, talc, polyethylene glycol, and Tween80 and dispersing them, to prepare a coating solution. Sugar spheres were put into a fluidized bed granulation-coating machine, spraying the coating solution, to prepare a first coated material.

[61]

[62] **2. Second coating**

[63] Hydroxypropyl methylcellulose, polyethylene glycol, sodium hydroxide, simethicone, and talc were added and dissolved in purified water to prepare a coating solution. The first coated materials were put into a fluidized bed granulation-coating machine, spraying the coating solution to prepare a second coated material.

[64]

[65] **3. Blending and tableting**

[66] The second coated material, sodium bicarbonate, copovidone, and crospovidone were added in a mixer to be blended, followed by adding sodium stearyl fumarate to prepare granules. The granules were tableted.

[67]

[68] **4. Third coating**

[69] Hydroxypropyl methylcellulose, titanium oxide, talc, polyethylene glycol, yellow iron oxide, red iron oxide, and black iron oxide were added in purified water to prepare a coating solution. The core tablets were put into a coating machine, spraying the coating solution, coating, and drying to obtain the final film coated tablet.

[70]

[71] **[Comparative Examples 2 and 3]**

[72] Preparation of a tablet of esomeprazole comprising hydroxypropyl methylcellulose (HPMC) or polyvinyl alcohol (PVA) as a coating agent

[73] The tablets of Comparative Examples 2 and 3 were prepared based on the method for preparing a tablet provided in Example 1, provided that Comparative Examples 2 and 3 used HPMC, instead of PVA, as a second coating agent and a third coating agent, respectively.

[74] The type of coating agent used in the preparation of Example 1 and Comparative Examples 1 to 3 are shown in Tablet 1 below.

[75]

[76] [Table 1]

	Second coating agent	Third coating agent
Example 1	PVA	PVA
Comparative Example 1	HPMC	HPMC
Comparative Example 2	HPMC	PVA
Comparative Example 3	PVA	HPMC

[77]

[78] **[Test Example 1]**

[79] **Impurities test**

[80] Stability test on the tablets of Example 1 and Comparative Examples 1 to 3 was carried out at accelerated conditions. The amount of impurities was measured by using the analytical condition below.

[81] <Analytical condition >

[82] 1) Detector: UV spectrophotometer (measurement wavelength: 305 nm)

[83] 2) Column: Phenomenex Luna C<sub>18</sub> (4.6 X 150 mm, 3 μm) or equivalent column

[84] 3) Injection volume: 50 μL

[85] 4) Flow rate: 1.0 mL/min

[86] 5) Column temperature: Constant temperature near 30°C

[87] 6) Sample temperature: Constant temperature near 4°C

[88] 7) Mobile phase:

[89] Mobile phase A - A solution where a mixture liquid of buffer solution at pH 8.7, acetonitrile, and methanol (7:2:1) was adjusted to have pH 8.7 with n-butylamine

[90] Mobile phase B - Buffer solution at pH 8.7 and acetonitrile (2:8)

[91]

Time (min)	Mobile phase A	Mobile phase B
0	100	0
20	100	0
25	70	30
35	80	20
40	80	20
45	100	0
50	100	0

[92] The buffer solution at pH 8.7 was prepared as follows: 0.71 g of sodium perchlorate (NaClO<sub>4</sub>) and 5 mL of n-butylamine were taken to be put in an 1L volumetric flask, followed by filling the flask with purified water up to the calibration mark and adjusting the pH to 8.7 with perchloric acid.

[93] The test results of impurities were shown in Tables 2 to 4 below.

[94]

[95] [Table 2]

**Amount of omeprazole sulfone (Specification: not more than 0.5%)**

	Initial state	1 month at accelerated conditions	3 months at accelerated conditions
Example 1	0.08 %	0.11 %	0.15 %
Comparative Example 1	0.10 %	0.19 %	0.39 %
Comparative Example 2	0.10 %	0.15 %	0.29 %
Comparative Example 3	0.10 %	0.15 %	0.29 %

[96] As shown in Table 2 above, it was confirmed that the tablet of Example 1 had the smallest amount of omeprazole sulfone, and thus was most stable. In case of 3 months at accelerated conditions, Comparative Examples 1 to 3 had 2 times more of the impurities amount of omeprazole sulfone than Example 1.

[97] Further, Comparative Example 1 using HPMC, instead of PVA, as a coating agent in both the second and third layers showed low stability to Comparative Examples 2 and 3 using PVA as a coating agent in either one of the second or third layer.

[98]

[99] [Table 3]

**Amount of individual unknown impurities (Specification: not more than 0.2%)**

	Initial state	1 month at accelerated conditions	3 months at accelerated conditions
Example 1	0.01 %	0.05 %	0.10 %
Comparative Example 1	0.09 %	0.24 %	0.51 %
Comparative Example 2	0.06 %	0.19 %	0.32 %
Comparative Example 3	0.06 %	0.19 %	0.32 %

[100] As shown in Table 3 above, it was confirmed that the tablet of Example 1 had the smallest amount of individual unknown impurities, and thus was most stable. In case of 1 month and 3 months at accelerated conditions, Comparative Examples 1 to 3 had almost 3 to 5 times more of the amount of individual unknown impurities than Example 1. In case of 3 months at accelerated conditions, the amount of impurities in Comparative Examples 1 to 3 was over the specification of 0.2%, which means that the results of stability test did not meet the acceptance criteria.

[101] Further, Comparative Example 1 using HPMC, instead of PVA, as a coating agent in both the second and third layers showed inferior stability to Comparative Examples 2 and 3 using PVA as a coating agent in either one of the second or third layer.

[102] [Table 4]

Amount of total impurities (Specification: not more than 2.0%)

	Initial state	1 month at accelerated condition	3 months at accelerated conditions
Example 1	0.04 %	0.32 %	0.87 %
Comparative Example 1	0.29 %	1.08 %	1.11 %
Comparative Example 2	0.19 %	0.58 %	1.33 %
Comparative Example 3	0.19 %	0.58 %	1.33 %

[103] As shown in Table 4 above, it was confirmed that the tablet of Example 1 had the smallest amount of the total impurities, and thus was most stable.

[104] In conclusion, it was confirmed that the tablet of Example 1 exerts remarkably improved stability in the amount of individual unknown impurities and total impurities, in comparison with the tablets of Comparative Examples 1 to 3.

[105] Further, the most improved stability was obtained when using polyvinyl alcohol as a coating agent for preventing the contact between omeprazole and sodium bicarbonate, and also using polyvinyl alcohol as a coating agent for coating the outer part of a tablet.

## Claims

- [Claim 1] A pharmaceutical formulation characterized in comprising the first layer comprising omeprazole, its enantiomer, or its pharmaceutically acceptable salt;  
the second layer comprising polyvinyl alcohol as a coating agent; and  
the third layer comprising sodium bicarbonate as an antacid.
- [Claim 2] The pharmaceutical formulation according to Claim 1, characterized in further comprising the fourth layer comprising polyvinyl alcohol as a coating agent.
- [Claim 3] The pharmaceutical formulation according to Claim 2 characterized in that the coating agent in the second and fourth layers is comprised in 0.1 to 7 parts by weight based on 1 part by weight of omeprazole, its enantiomer or its pharmaceutically acceptable salt.
- [Claim 4] The pharmaceutical formulation according to Claim 3, characterized in that the coating agent in the second and fourth layers is comprised in 0.5 to 5 parts by weight based on 1 part by weight of omeprazole, its enantiomer or its pharmaceutically acceptable salt.
- [Claim 5] The pharmaceutical formulation according to Claim 1, characterized in that omeprazole, its enantiomer, or its pharmaceutically acceptable salt is esomeprazole.
- [Claim 6] The pharmaceutical formulation according to Claim 1, characterized in that omeprazole, its enantiomer, or its pharmaceutically acceptable salt is magnesium salt of esomeprazole.
- [Claim 7] A method for preparing a pharmaceutical formulation comprising omeprazole, its enantiomer, or its pharmaceutically acceptable salt; and sodium bicarbonate, characterized in comprising the steps:  
first coating a core with a coating solution comprising omeprazole, its enantiomer, or its pharmaceutically acceptable salt to prepare a first coated material;  
coating the first coated material with a second coating solution comprising polyvinyl alcohol to prepare a second coated material;  
tableting the second coated material with sodium bicarbonate to prepare a core tablet; and  
coating the core tablet with a third coating solution comprising polyvinyl alcohol.
- [Claim 8] A method for preparing a pharmaceutical formulation comprising 20 mg or 40 mg of esomeprazole magnesium trihydrate based on the

weight of esomeprazole, and 800 mg of sodium bicarbonate, characterized in comprising the steps:

first coating a core with a coating solution comprising esomeprazole magnesium trihydrate to prepare a first coated material;

coating the first coated material with a second coating solution comprising polyvinyl alcohol to prepare a second coated material;

tableting the second coated material with sodium bicarbonate to prepare a core tablet; and

coating the core tablet with a third coating solution comprising polyvinyl alcohol.

**A. CLASSIFICATION OF SUBJECT MATTER**

**A61K 9/28(2006.01)i, A61K 9/20(2006.01)i, A61K 9/16(2006.01)i, A61K 9/50(2006.01)i, A61K 31/4439(2006.01)i, A61P 1/04(2006.01)i**

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

A61K 9/28; A61K 31/426; A61K 31/4439; A61K 9/16; A61K 9/22; A61K 9/24; A61K 9/48; A61K 9/50; A61K 9/20; A61P 1/04

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Korean utility models and applications for utility models

Japanese utility models and applications for utility models

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

eKOMPASS(KIPO internal) & Keywords:omeprazole, polyvinyl alcohol, sodium bicarbonate, coating, core tablet

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 6183776 B1 (DEPUI, HELENE et al.) 06 February 2001 See claims 2-8; column 3, lines 30-40; column 9, lines 15-24 and 46-56; column 10, lines 5-12; column 11, lines 12-16, 19-30 and 44-46; figure 3.	1-8
X	WO 2005-092297 A2 (TEVA PHARMACEUTICAL INDUSTRIES LTD. et al.) 06 October 2005 See claims 1-4, 8, 9, 14, 17, 19, 24, 25, 29 and 47.	1-6
A	KR 10-2017-0076494 A (HUONS CO., LTD.) 04 July 2017 See the whole document.	1-8
A	US 2012-0121664 A1 (PETTERSSON, ANDERS et al.) 17 May 2012 See the whole document.	1-8
A	KR 10-2005-0061647 A (KOREA UNITED PHARM. INC.) 23 June 2005 See the whole document.	1-8
A	US 2005-0266071 A1 (OLMSTEAD, KAY et al.) 01 December 2005 See the whole document.	1-8

Further documents are listed in the continuation of Box C.

See patent family annex.

\* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

29 April 2019 (29.04.2019)

Date of mailing of the international search report

**29 April 2019 (29.04.2019)**

Name and mailing address of the ISA/KR


International Application Division  
Korean Intellectual Property Office  
189 Cheongsa-ro, Seo-gu, Daejeon, 35208, Republic of Korea

Facsimile No. +82-42-481-8578

Authorized officer

KAM, Yoo Lim

Telephone No. +82-42-481-3516



**INTERNATIONAL SEARCH REPORT**

Information on patent family members

International application No.

**PCT/KR2019/001183**

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 6183776 B1	06/02/2001	AR 005281 A1	28/04/1999
		AT 228009 T	15/12/2002
		AU 1324197 A	01/08/1997
		AU 712669 B2	11/11/1999
		BR 9607350 A	30/12/1997
		BR 9607350 B1	10/08/2010
		CA 2213996 A1	17/07/1997
		CA 2213996 C	29/08/2006
		CN 1080125 C	06/03/2002
		CN 1183047 A	27/05/1998
		CZ 293583 B6	16/06/2004
		CZ 9702747 A3	18/03/1998
		DE 69624907 T2	21/08/2003
		DE 69624907 T3	14/01/2010
		DK 0813424 T3	10/03/2003
		DK 0813424 T4	09/11/2009
		EE 04002 B1	15/04/2003
		EE 9700192 A	16/02/1998
		EG 23821 A	19/09/2007
		EP 0813424 A1	20/11/2002
		EP 0813424 B1	20/11/2002
		EP 0813424 B2	05/08/2009
		ES 2185817 T3	01/05/2003
		ES 2185817 T5	24/11/2009
		HK 1001763 A1	28/02/2003
		HK 1017992 A1	01/11/2002
		HU 229153 B1	30/09/2013
		HU 9904024 A2	28/05/2000
		HU 9904024 A3	28/03/2002
		IL 121651 A	29/05/2003
		IS 2716 B	15/02/2011
		IS 4548 A	20/08/1997
		JP 11-501950 A	16/02/1999
		KR 10-0490075 B1	08/09/2005
		MX 9706785 A	29/11/1997
		NO 326656 B1	26/01/2009
		NO 974071 A	17/10/1997
		NZ 325977 A	25/02/1999
		PL 187075 B1	31/05/2004
		PL 322175 A1	19/01/1998
		PT 813424 E	31/03/2003
		RU 2179453 C2	20/02/2002
		SA 880 B1	04/06/2006
		SK 116997 A3	06/05/1998
		SK 283695 B6	02/12/2003
		TR 199700916 T1	21/12/1997
		TW 464514 B	21/11/2001
		WO 97-25066 A1	17/07/1997
		ZA 9610935 B	08/07/1997

## INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

PCT/KR2019/001183

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2005-092297 A2	06/10/2005	CA 2558535 A1	06/10/2005
		CN 1964704 A	16/05/2007
		EP 1720527 A2	15/11/2006
		IL 177869 A	31/12/2006
		JP 2007-526319 A	13/09/2007
		MX PA06009991 A	10/04/2007
		US 2005-0214371 A1	29/09/2005
		US 2005-0214372 A1	29/09/2005
		WO 2005-092297 A3	12/10/2006
		KR 10-2017-0076494 A	04/07/2017
US 2012-0121664 A1	17/05/2012	AU 2003-267924 A1	04/05/2004
		AU 2003-267924 B2	11/12/2008
		AU 2003-267924 C1	20/09/2012
		CA 2501201 A1	29/04/2004
		CA 2501201 C	08/01/2013
		CN 1726048 A	25/01/2006
		CN 1726048 B	30/05/2012
		EP 1558288 A1	03/08/2005
		EP 2258341 A2	08/12/2010
		EP 2258341 A3	29/08/2012
		IL 167850 A	05/02/2006
		IL 220775 A	30/08/2012
		JP 2006-505566 A	16/02/2006
		JP 2011-057714 A	24/03/2011
		KR 10-1139862 B1	03/07/2012
		KR 10-2005-0083770 A	26/08/2005
		MX PA05004118 A	05/10/2005
		NO 20052019 A	15/06/2005
		NZ 539262 A	30/04/2008
		PL 376178 A1	27/12/2005
		RU 2005114612 A	10/10/2005
		RU 2340358 C2	10/12/2008
		US 2006-0115530 A1	01/06/2006
US 2007-0031497 A1	08/02/2007		
US 2010-0151013 A1	17/06/2010		
US 2013-0017263 A1	17/01/2013		
US 7771747 B2	10/08/2010		
US 7785626 B2	31/08/2010		
WO 2004-035090 A1	29/04/2004		
KR 10-2005-0061647 A	23/06/2005	KR 10-0581967 B1	22/05/2006
		WO 2005-058282 A1	30/06/2005
US 2005-0266071 A1	01/12/2005	AU 2005-331781 A1	04/01/2007
		AU 2005-331781 A8	11/12/2008
		AU 2005-331781 B2	29/09/2011
		AU 2005-331781 C1	04/04/2013
		AU 2011-265561 A1	02/02/2012

**INTERNATIONAL SEARCH REPORT**

Information on patent family members

International application No.

**PCT/KR2019/001183**

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
		AU 2011-265561 B2	08/11/2012
		CA 2566655 A1	08/12/2005
		CA 2566655 C	16/04/2013
		CA 2609627 A1	30/11/2006
		CA 2609627 C	24/10/2017
		EP 1750767 A1	14/02/2007
		JP 2008-500365 A	10/01/2008
		MX PA06013585 A	22/07/2009
		US 2006-0147522 A1	06/07/2006
		US 2015-0044303 A1	12/02/2015
		US 8815916 B2	26/08/2014
		US 8906940 B2	09/12/2014
		WO 2005-115474 A1	08/12/2005
		WO 2005-115474 B1	23/02/2006
		WO 2006-127044 A2	30/11/2006
		WO 2006-127044 A3	09/08/2007